As a researcher, what is more important to you than a record of your research and scholarship? A Digital Persistent Identifier, or DPI, distinguishes you and your work from that of your peers. Graphic by Miguel Tovar/University of Houston

Every researcher needs a Digital Persistent Identifier.

As a researcher, what is more important to you than a record of your research and scholarship? A Digital Persistent Identifier, or DPI, distinguishes you and your work from that of your peers – and having one will be mandated for those receiving federal funding. Let’s take a deeper look at why this number is so important. We’ll also compare the different platforms— ORCID, Web of Science, Scopus and Google Scholar — so that you can be sure your publications, presentations, peer reviews and even information about who is citing you are being properly stored and accessed.

ORCID

There are many types of profiles and DPIs that can meet your needs, but there’s no silver bullet. Placing your work onto multiple platforms is necessary according to Andrea Malone, Research Visibility and Impact Coordinator at UH Libraries. She cautions researchers to “be realistic about how many identifiers you can maintain.”

The most popular is ORCID, which stands for Open Researcher and Contributor ID. It’s free to set up, and there is no chance of accidentally or on-purpose having multiple ORCID accounts – it’s assigned to you like a social security number and follows you, the researcher. This comes in particularly especially handy for researchers with common names.

An identifier is federally mandated for those receiving governmental funds. It is not specified that ORCID must be that identifier. For example, according to Malone: “a Web of Science profile also assigns an identifier, which would also satisfy the mandate.” But most researchers choose ORCID because it’s publicly available with no access restrictions.

While an ORCID number is free for researchers, there is a subscription fee for an institution to be associated with ORCID. Information will not pre-populate in an ORCID profile and it doesn’t track citation counts – it only shows what you put in. There are, however, linking wizards that allow you to link from Web of Science and Scopus to your ORCID account. If you choose this option, citations will automatically populate in your ORCID profile. It’s up to the researcher to doublecheck to be sure the information has automated, however.

Google Scholar

Google Scholar is a profile, not an identifier, so it does not comply with federal funding requirements. It is free, however, and it pulls from the open web. You can choose to have your list of articles updated automatically, review the updates yourself or manually update your articles at any time. Google Scholar also specifies which articles are open access. A PDF or HTML icon will appear on the righthand side of each citation for one to download articles.

Web of Science Vs. Scopus

Scopus is known for covering more journals and a wider range of metrics to evaluate research impact than Web of Science. Different platforms are a go-to for certain disciplines – for example, Web of Science is usually associated with hard sciences, although investigators in the social sciences and humanities also place their work on this platform from time to time. It’s a good idea to check out which platforms others in your discipline are using for their profiles.

Staying up-to-date

Of course, DPIs don’t work as intended unless researchers keep their profiles current. That means you need to check your profile after every publication and every time you switch to a new institution. Just as you would update your CV, you must update your ORCID or other DPI profile.

One tactic Malone suggests is setting a schedule either biweekly or monthly to check all your profiles. “One thing that’s helpful is that with all of them, you can set up alerts and create an alert as often as you want,” Malone goes on. “At that time, the program will scrawl the content within the source and alert you to anytime any of your publications appear in their database.”

The Big Idea

No one tool can paint a complete picture of all your scholarship. Be strategic and intentional about which platforms you use. Consider your audience, the platforms others in your discipline use and make sure you have an ORCID profile to comply with the federal mandate. But be careful not to sign up for more than you can feasibly maintain and keep current.

------

This article originally appeared on the University of Houston's The Big Idea. Sarah Hill, the author of this piece, is the communications manager for the UH Division of Research.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston edtech company closes oversubscribed $3M seed round

fresh funding

Houston-based edtech company TrueLeap Inc. closed an oversubscribed seed round last month.

The $3.3 million round was led by Joe Swinbank Family Limited Partnership, a venture capital firm based in Houston. Gamper Ventures, another Houston firm, also participated with additional strategic partners.

TrueLeap reports that the funding will support the large-scale rollout of its "edge AI, integrated learning systems and last-mile broadband across underserved communities."

“The last mile is where most digital transformation efforts break down,” Sandip Bordoloi, CEO and president of TrueLeap, said in a news release. “TrueLeap was built to operate where bandwidth is limited, power is unreliable, and institutions need real systems—not pilots. This round allows us to scale infrastructure that actually works on the ground.”

True Leap works to address the digital divide in education through its AI-powered education, workforce systems and digital services that are designed for underserved and low-connectivity communities.

The company has created infrastructure in Africa, India and rural America. Just this week, it announced an agreement with the City of Kinshasa in the Democratic Republic of Congo to deploy a digital twin platform for its public education system that will allow provincial leaders to manage enrollment, staffing, infrastructure and performance with live data.

“What sets TrueLeap apart is their infrastructure mindset,” Joe Swinbank, General Partner at Joe Swinbank Family Limited Partnership, added in the news release. “They are building the physical and digital rails that allow entire ecosystems to function. The convergence of edge compute, connectivity, and services makes this a compelling global infrastructure opportunity.”

TrueLeap was founded by Bordoloi and Sunny Zhang and developed out of Born Global Ventures, a Houston venture studio focused on advancing immigrant-founded technology. It closed an oversubscribed pre-seed in 2024.

Texas space co. takes giant step toward lunar excavator deployment

Out of this world

Lunar exploration and development are currently hampered by the fact that the moon is largely devoid of necessary infrastructure, like spaceports. Such amenities need to be constructed remotely by autonomous vehicles, and making effective devices that can survive the harsh lunar surface long enough to complete construction projects is daunting.

Enter San Antonio-based Astroport Space Technologies. Founded in San Antonio in 2020, the company has become a major part of building plans beyond Earth, via its prototype excavator, and in early February, it completed an important field test of its new lunar excavator.

The new excavator is designed to function with California-based Astrolab's Flexible Logistics and Exploration (FLEX) rover, a highly modular vehicle that will perform a variety of functions on the surface of the moon.

In a recent demo, the Astroport prototype excavator successfully integrated with FLEX and proceeded to dig in a simulated lunar surface. The excavator collected an average of 207 lbs (94kg) of regolith (lunar surface dust) in just 3.5 minutes. It will need that speed to move the estimated 3,723 tons (3,378 tonnes) of regolith needed for a lunar spaceport.

After the successful test, both Astroport and Astrolab expressed confidence that the excavator was ready for deployment. "Leading with this successful excavator demo proves that our technology is no longer theoretical—it is operational," said Sam Ximenes, CEO of Astroport.

"This is the first of many implements in development that will turn Astrolab's FLEX rover into the 'Swiss Army Knife' of lunar construction. To meet the infrastructure needs of the emerging lunar economy, we must build the 'Port' before the 'Ship' arrives. By leveraging the FLEX platform, we are providing the Space Force, NASA, and commercial partners with a 'Shovel-Ready' construction capability to secure the lunar high ground."

"We are excited to provide the mobility backbone for Astroport's groundbreaking construction technology," said Jaret Matthews, CEO of Astrolab, in a release. "Astrolab is dedicated to establishing a viable lunar ecosystem. By combining our FLEX rover's versatility with Astroport's civil engineering expertise, we are delivering the essential capabilities required for a sustainable lunar economy."

---

This article originally appeared on CultureMap.com.

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.